Abstract 876P
Background
Despite surgical resection, Oral Potentially Malignant Disorders show a rate of malignant transformation varying from 3% to 17.5%. Clinical and histological factors outside dysplasia and previous oral cavity carcinoma failed to identify OPMDs at higher risk of malignant transformation (MF). We previously identified six clusters of transcriptomic data able to stratify Head and Neck Squamous Cell Carcinoma (HNSCC) that also applied to OPMD. The primary objective of the current study was to validate the stratification by the transcriptional signature in an independent series of dysplastic OPMD.
Methods
We collected a retrospective series (3/1996 to 11/2019) of completely excised OPMDs with any grade of dysplasia at the University of Brescia. Clinical/histological data were retrieved. Library preparation for gene expression profiling was conducted QuantSeq 3'mrna-seq (Lexogen) and pooled libraries were sequenced by NextSeq500 (Illumina). Finally, previously identified molecular clusters based on main biological characteristics and de-regulated signaling pathways were associated with the risk of MF.
Results
We identified 106 consecutive patients with OPMDs. Of these, 66 had available material for gene expression analysis. A slight majority were male (53.4%), with a median age of 65 years (33-95); 17% had a previous diagnosis of HNSCC. With a median follow-up of 53 months (IQR 91), 23% experienced a MF with a median time to transformation of 30 months (3—195). After stratification based on our previously reported clusters, OPMDs were classified as mesenchymal, hypoxia, defense response, classical, and immunoreactive clusters constituted 8%, 15%, 27%, 9%, and 41% of our cohort, respectively. Hypoxia cluster showed a higher risk of malignant transformation (p<0.0001).
Conclusions
OPMDs gene expression clustering allows stratifying patients according to different risk of MF. Among them, hypoxia cluster had the highest probability of cancerization. A more in-depth analysis of this cluster is required, both to better characterize the mechanisms of MF and to develop customized prevention strategies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Medical Oncology Unit, Department of Medical & Surgical Specialties, Radiological Sciences & Public Health, University of Brescia, ASST Spedali Civili, 25123 Brescia, Italy.
Funding
Funded by AIRC (IG 21740 to PB).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
890P - Real-world survival outcomes and survival risk factors in elderly patients with locally advanced squamous cell carcinoma of the head and neck
Presenter: Nabil Saba
Session: Poster session 12
891P - Changing landscape of head and neck squamous cell carcinoma (HNSCC) treatment and survival in Thailand: A 13-year multicenter retrospective study of 6,319 patients
Presenter: Nuttapong Ngamphaiboon
Session: Poster session 12
892P - Real-world data validation of university of San Diego nomogram for the prediction of benefit of intensive treatment for locoregionally advanced head and neck cancer
Presenter: Javier Caballero Daroqui
Session: Poster session 12
893P - Tumor node stage shift following leukocyte interleukin injection neoadjuvant extends overall survival in treatment-naïve locally advanced oral cavity/soft palate squamous cell carcinoma
Presenter: Jozsef Timar
Session: Poster session 12
894P - Is pathological complete response (PCR) a surrogate endpoint of overall survival in patients with technically unresectable oral cavity cancers? A real-world data study of 900 plus patients
Presenter: Shatabdi Chakraborty
Session: Poster session 12
896P - Efficacy and safety of pembrolizumab with preoperative neoadjuvant chemotherapy in patients with resectable locally advanced head and neck squamous cell carcinomas
Presenter: Kai Wang
Session: Poster session 12
897P - Nanosomal docetaxel lipid suspension (NDLS) or docetaxel based neoadjuvant therapy in Head and neck squamous cell carcinoma: Post hoc analysis of a prospective, randomized study
Presenter: Darshit Shah
Session: Poster session 12
898P - Meta-analysis of two placebo-controlled trials of avasopasem manganese (AVA) in patients with locally advanced, head & neck cancer (LAHNC)
Presenter: Neal Dunlap
Session: Poster session 12
899P - Impact of COVID-19 pandemic on treatment and survival in head and neck squamous cell carcinoma (HNSCC) patients (IMPACCT Study)
Presenter: Berta Vilar Anglada
Session: Poster session 12